Damora Therapeutics, Inc. Ordinary Shares
DMRA
25 hedge funds and large institutions have $37.2M invested in Damora Therapeutics, Inc. Ordinary Shares in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 8 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0.15% less ownership
Funds ownership: 1.8% → 1.65% (-0.15%)
4% less funds holding
Funds holding: 26 → 25 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
35% less capital invested
Capital invested by funds: $57.4M → $37.2M (-$20.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$1.04M |
| 2 |
Two Sigma Investments
New York
|
+$652K |
| 3 |
Millennium Management
New York
|
+$356K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$321K |
| 5 |
Renaissance Technologies
New York
|
+$270K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.72M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.58M |
| 3 |
MC
Maverick Capital
Dallas,
Texas
|
-$1.8M |
| 4 |
ACM
Asymmetry Capital Management
San Francisco,
California
|
-$308K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$274K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCM
26
Soleus Capital Management
Greenwich,
Connecticut
| – | -$2.72M | -21,526 | Closed |
|
|
MC
27
Maverick Capital
Dallas,
Texas
| – | -$1.8M | -14,252 | Closed |
|
|
ACM
28
Asymmetry Capital Management
San Francisco,
California
| – | -$308K | -2,439 | Closed |
|
|
29
Tudor Investment Corp
Stamford,
Connecticut
| – | -$274K | -2,164 | Closed |
|
|
BAM
30
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$128K | -1,010 | Closed |
|
|
XT
31
XTX Topco
George Town,
Cayman Islands
| – | -$56K | -441 | Closed |
|
32
UBS Group
Zurich,
Switzerland
| – | -$40K | -313 | Closed |
|
33
Morgan Stanley
New York
| – | -$1K | -4 | Closed |
|
DMRA Hedge Fund Activity: Q3 2021 in Review
25 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q3 2021, worth a combined $37.2M — down 35% from $57.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of DMRA and 7 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 8 added.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $1.04M. The largest seller was Soleus Capital Management, exiting entirely with an estimated $2.72M sold.
- 25 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q3 2021, down from 26 in Q2 2021.
- Funds reported $37.2M of Damora Therapeutics, Inc. Ordinary Shares stock for Q3 2021, down 35% quarter-over-quarter.
- 7 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q3 2021 and 8 closed out, a net change of -1 holder.
- The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q3 2021 was Two Sigma Advisers, an estimated $1.04M added.
- The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q3 2021 was Soleus Capital Management, an estimated $2.72M sold.
Based on aggregated 13F filings for Q3 2021.